SG11202109085YA - Anti-pd-l1 antibody and use thereof - Google Patents
Anti-pd-l1 antibody and use thereofInfo
- Publication number
- SG11202109085YA SG11202109085YA SG11202109085YA SG11202109085YA SG11202109085YA SG 11202109085Y A SG11202109085Y A SG 11202109085YA SG 11202109085Y A SG11202109085Y A SG 11202109085YA SG 11202109085Y A SG11202109085Y A SG 11202109085YA SG 11202109085Y A SG11202109085Y A SG 11202109085YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019075654 | 2019-02-21 | ||
PCT/CN2020/075983 WO2020169062A1 (en) | 2019-02-21 | 2020-02-20 | Anti-pd-l1 antibody and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202109085YA true SG11202109085YA (en) | 2021-09-29 |
Family
ID=72143305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202109085YA SG11202109085YA (en) | 2019-02-21 | 2020-02-20 | Anti-pd-l1 antibody and use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220073621A1 (en) |
EP (1) | EP3929213A4 (en) |
JP (1) | JP2022521305A (en) |
KR (1) | KR20210132664A (en) |
CN (1) | CN113574069A (en) |
AU (1) | AU2020225173A1 (en) |
BR (1) | BR112021016596A2 (en) |
CA (1) | CA3130807A1 (en) |
IL (1) | IL285569A (en) |
MX (1) | MX2021010116A (en) |
SG (1) | SG11202109085YA (en) |
WO (1) | WO2020169062A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022057061A1 (en) * | 2020-09-16 | 2022-03-24 | Suzhou Neologics Bioscience Co., Ltd. | Pd-l1 antibodies, fusion proteins, and uses thereof |
CN114634567A (en) * | 2020-12-16 | 2022-06-17 | 康诺亚生物医药科技(成都)有限公司 | Development and application of immunomodulator |
CN115073599B (en) * | 2021-03-16 | 2023-04-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind PD-L1 and uses thereof |
AU2022407242A1 (en) * | 2021-12-09 | 2024-06-20 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody-cytokine fusion proteins and applications thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101411165B1 (en) * | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
PE20120341A1 (en) * | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
MX343747B (en) * | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Targeted binding agents against b7-h1. |
RS61033B1 (en) * | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
MX2017016851A (en) * | 2016-03-04 | 2018-04-30 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof. |
SG11201809336QA (en) * | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
-
2020
- 2020-02-20 SG SG11202109085YA patent/SG11202109085YA/en unknown
- 2020-02-20 CN CN202080015885.6A patent/CN113574069A/en active Pending
- 2020-02-20 BR BR112021016596A patent/BR112021016596A2/en not_active Application Discontinuation
- 2020-02-20 AU AU2020225173A patent/AU2020225173A1/en not_active Abandoned
- 2020-02-20 KR KR1020217027888A patent/KR20210132664A/en unknown
- 2020-02-20 EP EP20758681.9A patent/EP3929213A4/en not_active Withdrawn
- 2020-02-20 MX MX2021010116A patent/MX2021010116A/en unknown
- 2020-02-20 CA CA3130807A patent/CA3130807A1/en active Pending
- 2020-02-20 JP JP2021549339A patent/JP2022521305A/en active Pending
- 2020-02-20 WO PCT/CN2020/075983 patent/WO2020169062A1/en unknown
- 2020-08-20 US US17/430,396 patent/US20220073621A1/en active Pending
-
2021
- 2021-08-12 IL IL285569A patent/IL285569A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3130807A1 (en) | 2020-08-27 |
CN113574069A (en) | 2021-10-29 |
WO2020169062A1 (en) | 2020-08-27 |
IL285569A (en) | 2021-09-30 |
JP2022521305A (en) | 2022-04-06 |
AU2020225173A1 (en) | 2021-08-12 |
EP3929213A1 (en) | 2021-12-29 |
US20220073621A1 (en) | 2022-03-10 |
KR20210132664A (en) | 2021-11-04 |
BR112021016596A2 (en) | 2021-12-21 |
EP3929213A4 (en) | 2023-03-08 |
MX2021010116A (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006904B (en) | Anti-il-4r antibody and use thereof | |
SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
IL273411A (en) | Anti-pd-l1 antibody and uses thereof | |
IL278846A (en) | Anti-cd3 antibodies and uses thereof | |
IL279455A (en) | Anti-pd-1 antibodies and uses thereof | |
IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
ZA202006255B (en) | Anti-pd-l1 antibody and use thereof | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
EP3587453A4 (en) | Anti-pd-l1 antibody and application thereof | |
SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
EP3612565A4 (en) | Anti-pd-l1 antibody and use thereof | |
IL285569A (en) | Anti-pd-l1 antibody and use thereof | |
IL268051A (en) | Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof | |
EP3901172A4 (en) | Humanized anti-pd-1 antibody and use thereof | |
IL276675A (en) | Anti-pd-1 antibodies and uses thereof | |
IL290256A (en) | Anti-pd-1 antibody and pharmaceutical use thereof | |
IL287690A (en) | Anti-hvem antibodies and use thereof | |
IL282708A (en) | Anti-tim-3 antibodies and their use | |
IL282707A (en) | Anti-tim-3 antibodies and their use | |
IL289354A (en) | Anti-cd154 antibodies and uses thereof | |
IL289656A (en) | Anti-tigit antibodies and application thereof | |
EP3733706A4 (en) | Anti-pd-l1 antibody and use thereof | |
SG11202111188VA (en) | Anti-cd40 antibody and use thereof | |
EP3774920A4 (en) | Anti-pd-l1 antibodies and use thereof | |
IL283180A (en) | Anti-pd-1 antibodies and uses thereof |